These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Hoogerbrugge PM, van Beusechem VW, Fischer A, Debree M, le Deist F, Perignon JL, Morgan G, Gaspar B, Fairbanks LD, Skeoch CH, Moseley A, Harvey M, Levinsky RJ, Valerio D. Gene Ther; 1996 Feb; 3(2):179-83. PubMed ID: 8867866 [Abstract] [Full Text] [Related]
7. In vivo kinetics of transduced cells in peripheral T cell-directed gene therapy: role of CD8+ cells in improved immunological function in an adenosine deaminase (ADA)-SCID patient. Kawamura N, Ariga T, Ohtsu M, Kobayashi I, Yamada M, Tame A, Furuta H, Okano M, Egashira M, Niikawa N, Kobayashi K, Sakiyama Y. J Immunol; 1999 Aug 15; 163(4):2256-61. PubMed ID: 10438969 [Abstract] [Full Text] [Related]
8. Adenosine deaminase deficiency. Hirschhorn R. Immunodefic Rev; 1990 Aug 15; 2(3):175-98. PubMed ID: 2078332 [Abstract] [Full Text] [Related]
10. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency. Carbonaro DA, Jin X, Petersen D, Wang X, Dorey F, Kil KS, Aldrich M, Blackburn MR, Kellems RE, Kohn DB. Mol Ther; 2006 Jun 15; 13(6):1110-20. PubMed ID: 16651028 [Abstract] [Full Text] [Related]
16. Visible integration of the adenosine deaminase (ADA) gene into the recipient genome after gene therapy. Egashira M, Ariga T, Kawamura N, Miyoshi O, Niikawa N, Sakiyama Y. Am J Med Genet; 1998 Jan 23; 75(3):314-7. PubMed ID: 9475605 [Abstract] [Full Text] [Related]
17. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID. Bordignon C, Mavilio F, Ferrari G, Servida P, Ugazio AG, Notarangelo LD, Gilboa E, Rossini S, O'Reilly RJ, Smith CA. Hum Gene Ther; 1993 Aug 23; 4(4):513-20. PubMed ID: 8399494 [Abstract] [Full Text] [Related]
18. Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase. Chun JD, Lee N, Kobayashi RH, Chaffee S, Hershfield MS, Stiehm ER. Ann Allergy; 1993 Jun 23; 70(6):462-6. PubMed ID: 8507039 [Abstract] [Full Text] [Related]
19. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies. Silver JN, Flotte TR. Pharmacogenomics; 2008 Jul 23; 9(7):947-68. PubMed ID: 18597656 [Abstract] [Full Text] [Related]
20. Hyperbilirubinemia and rapid fatal hepatic failure in severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID). Kühl JS, Schwarz K, Münch A, Schmugge M, Pekrun A, Meisel C, Wahn V, Ebell W, von Bernuth H. Klin Padiatr; 2011 Mar 23; 223(2):85-9. PubMed ID: 21271505 [Abstract] [Full Text] [Related] Page: [Next] [New Search]